Allogene Therapeutics and MD Anderson Announce Strategic Collaboration to Accelerate Advancement of Allogeneic CAR T Therapy (AlloCAR T™)

On October 15, 2020 Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) therapies for cancer, and The University of Texas MD Anderson Cancer Center reported a strategic five-year collaboration agreement for the preclinical and clinical investigation of AlloCAR T candidates across Allogene’s broad portfolio of hematologic and solid tumors (Press release, Allogene, OCT 15, 2020, View Source [SID1234568519]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"MD Anderson’s expertise in innovative clinical trials and well established translational research infrastructure will provide unique insights that will help expedite the development of AlloCAR T therapies," said Rafael Amado, M.D., Executive Vice President of Research and Development and Chief Medical Officer of Allogene. "Coupled with Allogene’s cell therapy expertise, we believe this institution-industry alliance could play an important role in bringing this next revolution in oncology treatment to patients."

Under the agreement, MD Anderson and Allogene will collaborate on the design and conduct of preclinical and clinical studies with oversight from a joint steering committee. Allogene will provide funding, developmental candidates, and other support. Responsibility for regulatory filings will be agreed upon by the joint steering committee.

"We share Allogene’s commitment to advancing novel therapies that will translate into effective treatments for cancer patients," said Christopher Flowers, M.D., ad interim division head of Cancer Medicine and chair of Lymphoma and Myeloma at MD Anderson. "This collaboration will enable us to work together closely to advance allogeneic cell therapies to better address significant unmet medical needs for patients across the spectrum of oncologic diseases."

eFFECTOR Appoints Premal Patel, M.D., Ph.D., as Chief Medical Officer

On October 15, 2020 eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, reported the appointment of Premal Patel, M.D., Ph.D., as chief medical officer (Press release, eFFECTOR Therapeutics, OCT 15, 2020, View Source [SID1234568518]). Dr. Patel will lead the clinical development of the company’s pipeline of cancer product candidates. He will also be a member of eFFECTOR’s executive management team.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Dr. Patel is an accomplished physician-scientist who has demonstrated expertise in developing oncology products across a number of mechanisms, including targeted agents, immuno-oncology and cell-based therapies," said Steve Worland, Ph.D., president and chief executive officer of eFFECTOR. "His experience will be invaluable as we evaluate tomivosertib combined with pembrolizumab in a randomized Phase 2 study in non-small cell lung cancer and advance zotatifin into expansion cohorts targeting specific patient populations."

Dr. Patel brings to eFFECTOR more than 15 years of healthcare industry experience in medical oncology drug development, thoughtfully combining clinical strategy with adept biomarker approaches. Most recently, Dr. Patel was chief medical officer at Lyell Immunopharma. Previously he served as senior vice president, head of early clinical drug development at Juno Therapeutics, where he led CAR-T efforts in multiple myeloma and all solid tumor CAR-T and TCR efforts. He has also served as vice president, head of early clinical development and translational research at Pfizer, where he led the allogenic CAR-T effort, along with immuno-oncology assets. Dr. Patel spent over seven years at Genentech, Research and Early Development leading clinical development for several agents, including atezolizumab + Avastin in renal cell carcinoma, and the AKT inhibitor ipatasertib across indications from inception to successful proof-of-concept at end of Phase 2.

Dr. Patel completed residencies in internal medicine at University of Washington and adult medical oncology at Memorial Sloan Kettering Cancer Center, where he researched targeted therapies for renal cell carcinoma. Dr. Patel received his M.D. and Ph.D. degrees at University of Washington and a B.S. in pharmacy from Rutgers University.

About Selective Translation Regulator Inhibitors

Selective Translation Regulator Inhibitors (STRIs) target the eukaryotic initiation factor 4F (eIF4F) complex and its activating kinases, MNK1/2. eIF4F is a key node where the RAS and PI3K pathways converge and controls production of multiple oncoproteins that are validated therapeutic targets, including several RTKs, RAS, Cyclin D, CDK4/6, estrogen receptor (ER) and Myc. Inhibiting eIF4A or eIF4FE, the catalytic subunits of eIF4F, leads to apoptosis in select cancer models. MNK inhibition delays T cell exhaustion while enhancing T cell central memory pool.

Genmab to Host Capital Markets Day

On October 15, 2020 Genmab A/S (Nasdaq: GMAB) reported that it will hold a Capital Markets Day for analysts and investors on November 13, 2020 from 8:30 AM EST / 2:30 PM CET to 11:00 AM EST / 5:00 PM CET (Press release, Genmab, OCT 15, 2020, View Source [SID1234568517]). The event will be webcast live from Genmab’s state-of-the-art R&D Center in Utrecht, the Netherlands, and from its new offices and laboratory facilities in Princeton, NJ, US. The Capital Markets Day will feature Genmab’s Executive Management Team and a variety of high-level Genmab speakers who will provide updates on Genmab’s business and the ways in which we are delivering on our commitments and evolving into a fully integrated biotech innovation powerhouse.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Topics to be discussed include an overview of our robust product pipeline with a focus on our exciting epcoritamab, tisotumab vedotin and DuoBody-PD-L1x4-1BB programs, a deep dive into our proprietary DuoBody technology and a look at how we are growing our capabilities across the company.

Fate Therapeutics Announces Presentations at the 2020 Society for Immunotherapy of Cancer Annual Meeting

On October 15, 2020 Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, reported that five abstracts for the Company’s induced pluripotent stem cell (iPSC) product platform were accepted for presentation at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) annual meeting being held virtually from November 9-14, 2020 (Press release, Fate Therapeutics, OCT 15, 2020, View Source [SID1234568511]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Accepted abstracts include clinical data from 15 patients in the dose-escalation stage of the Company’s Phase 1 clinical trial of FT500 in advanced solid tumors (NCT03841110), which includes nine patients in Regimen A (three once-weekly doses of FT500 for up to two 30-day cycles as monotherapy) and six patients in Regimen B (three once-weekly doses of FT500 for up to two 30-day cycles in combination with checkpoint inhibitor therapy). The Company is currently enrolling the dose-expansion stage of the Phase 1 clinical trial for patients with non-small cell lung cancer or classical Hodgkin lymphoma who are refractory to, or have relapsed on, checkpoint inhibitor therapy. Each patient in the dose-expansion stage is to receive three once-weekly doses of FT500 at 300 million cells per dose, each with IL-2 cytokine support, for up to two 30-day cycles in combination with the same checkpoint inhibitor on which the patient failed or relapsed.

Oral Presentation

Targeting pan-tumor associated antigen B7H3 via combination of tri-specific killer engager and off-the-shelf NK cell therapy enhances specificity and function against a broad range of solid tumors (#470)
Poster Presentations

Preclinical development of a novel iPSC-derived CAR-MICA/B NK cell immunotherapy to overcome solid tumor escape from NKG2D-mediated mechanisms of recognition and killing (#114)
Multi-antigen targeting of heterogenous solid tumors using CAR T cells secreting bi-specific T-cell engagers (#116)
iPSC-derived NK cells mediate robust anti-tumor activity against glioblastoma (#155)
Preliminary results of an ongoing phase I trial of FT500, a first-in-class, off-the-shelf, iPSC-derived NK cell therapy in advanced solid tumors (#380)
All abstracts are scheduled to be available on the SITC (Free SITC Whitepaper) website on November 9, 2020.

About Fate Therapeutics’ iPSC Product Platform
The Company’s proprietary induced pluripotent stem cell (iPSC) product platform enables mass production of off-the-shelf, engineered, homogeneous cell products that can be administered with multiple doses to deliver more effective pharmacologic activity, including in combination with other cancer treatments. Human iPSCs possess the unique dual properties of unlimited self-renewal and differentiation potential into all cell types of the body. The Company’s first-of-kind approach involves engineering human iPSCs in a one-time genetic modification event and selecting a single engineered iPSC for maintenance as a clonal master iPSC line. Analogous to master cell lines used to manufacture biopharmaceutical drug products such as monoclonal antibodies, clonal master iPSC lines are a renewable source for manufacturing cell therapy products which are well-defined and uniform in composition, can be mass produced at significant scale in a cost-effective manner, and can be delivered off-the-shelf for patient treatment. As a result, the Company’s platform is uniquely capable of overcoming numerous limitations associated with the production of cell therapies using patient- or donor-sourced cells, which is logistically complex and expensive and is subject to batch-to-batch and cell-to-cell variability that can affect clinical safety and efficacy. Fate Therapeutics’ iPSC product platform is supported by an intellectual property portfolio of over 300 issued patents and 150 pending patent applications.

About FT500
FT500 is an investigational, universal, off-the-shelf natural killer (NK) cell cancer immunotherapy derived from a clonal master induced pluripotent stem cell (iPSC) line. The product candidate is being investigated in an open-label, multi-dose Phase 1 clinical trial for the treatment of advanced solid tumors (NCT03841110). The study is designed to assess the safety and tolerability of FT500 as a monotherapy and in combination with one of three FDA-approved immune checkpoint inhibitor (ICI) therapies – nivolumab, pembrolizumab or atezolizumab – in patients that have failed prior ICI therapy. Despite the clinical benefit conferred by approved ICI therapy against a variety of tumor types, these therapies are not curative and, in most cases, patients either fail to respond or their disease progresses on these agents. One common mechanism of resistance to ICI therapy is associated with loss-of-function mutations in genes critical for antigen presentation. A potential strategy to overcome resistance is through the administration of allogeneic NK cells, which have the inherent capability to recognize and directly kill tumor cells with these mutations.

VBL Therapeutics Announces Additional New European Patent in the MOSPD2 Platform Technology, This Time for Treatment of Cancer

On October 15, 2020 VBL Therapeutics (Nasdaq: VBLT), reported that the European Patent Office (EPO) has granted Patent #3328401, which covers VBL’s proprietary investigational anti-MOSPD2 monoclonal antibodies to treat oncology conditions (Press release, VBL Therapeutics, OCT 15, 2020, View Source [SID1234568510]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

VBL has identified MOSPD2 as a novel target whose expression is induced in multiple tumors, including colon, esophagus, liver and breast among others. Expression of MOSPD2 plays a role in the ability of cancer cells to metastasize. The point that MOSPD2 is expressed abundantly and specifically on tumors, but not on normal tissues, makes it a good and novel target for killing of tumor cells.

"This new patent is an important milestone achieved by VBL in securing intellectual property protection for our MOSPD2 program and for targeting MOSPD2 for anti-cancer therapy," said Erez Feige, Ph.D, MBA, VP Business Operations at VBL. Earlier this week, VBL announced the grant of another European Patent #3328408, which covers VBL’s proprietary antibodies to treat inflammatory conditions.

The claims in the granted patent cover the use of such anti-MOSPD2 antibody/antibody fragment to treat a wide range of cancers which express MOSPD2, including solid tumors and hematological cancers. The patent is expected to provide protection for VBL’s anti-MOSPD2 platform, until at least July 2036.

About VBL’s VB-600 Platform
VBL is conducting two parallel drug development programs that are exploring the potential of MOSPD2 (motile sperm domain-containing protein 2), a protein that VBL has identified as a key regulator of cell motility, as a therapeutic target for inflammatory diseases and cancer. The Company’s VB-600 platform comprises classical anti-MOSPD2 monoclonal antibody candidates for inflammatory indications, as well as bi-specific antibody candidates for oncology.